



**NORTHSIDE HOSPITAL  
CANCER INSTITUTE**

LEUKEMIA PROGRAM

*The Blood & Marrow  
Transplant Group*  
O F G E O R G I A

## Leukemia Program

# Clinical Trial Opening



## C262

Open for Enrollment C-262: Phase 3 Open-Label, Multicenter, and Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation.

[northside.com/leukemia](http://northside.com/leukemia)

[bmtga.com](http://bmtga.com)

NHCI Leukemia Program in collaboration with Astellas Pharma Inc. is offering ASP2215 therapy in subjects with FLT3-mutated AML who are refractory to or have relapsed after first-line AML therapy. Patients with the FLT3 mutation have poor prognoses including higher relapse rates, shorter durations of remission from initial therapy, and reduced disease-free survival.

Patients will be randomized in a 2:1 ratio to receive ASP2215 or pre-selected salvage chemotherapy. ASP2215 is an oral tablet that patients will take once daily without food in continuous 28-day cycles.

## **STUDY OBJECTIVES**

- › Determine the clinical benefit of ASP2215 therapy when comparing overall survival (OS) to salvage chemotherapy.
- › Determine overall efficacy in event-free survival of ASP2215 compared to salvage chemotherapy.
- › Determine overall efficacy in CR rate of ASP2215 compared to salvage chemotherapy.

**Patient MUST be FLT3 positive to be considered for this clinical research trial.**

If you have any questions, would like to discuss study logistics, or the eligibility of any patients, please contact Stacey Brown, NH BMT/Leukemia Clinical Research Manager, at **404-851-8238** or [stacey.brown@northside.com](mailto:stacey.brown@northside.com).



## **NORTHSIDE HOSPITAL CANCER INSTITUTE**

5670 Peachtree Dunwoody Road  
Suite 1000  
Atlanta, GA 30342

Presorted  
First-Class Mail  
**U.S. Postage PAID**  
Atlanta, GA  
Permit #1713